Investigational drug · Phase 3
Clifutinib
Also called: HEC73543
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leukemia, Acute Myeloid (AML), Acute Myeloid Leukemia, Adult.
Phase 3Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Clifutinib"
First trial start
2022
Oct 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Clifutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Acute Myeloid (AML)
- Acute Myeloid Leukemia, Adult
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Clifutinib" as an intervention, largest first.
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT05586074 · 324 participants (planned) · Start Mar 3, 2023 · Primary completion Nov 30, 2027
Drug: Clifutinib; LoDAC and 4 more · For: Leukemia, Acute Myeloid (AML)
Sites: Hanzhou, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT05133882 · 133 participants (planned) · Start Oct 31, 2022 · Primary completion Dec 31, 2027
Drug: Clifutinib Besylate · For: Acute Myeloid Leukemia, Adult
Sites: Hanzhou, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT07341672 · 80 participants (planned) · Start Dec 31, 2026 · Primary completion Apr 23, 2027
Drug: Clifutinib; Itraconazole and 2 more · For: Healthy Adult Subject
Sites: Jinan, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT04827069 · 75 participants · Start May 18, 2018 · Primary completion Aug 21, 2023
Drug: Clifutinib Besylate · For: Acute Myeloid Leukemia
Sites: Hanzhou, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT05454098 · 40 participants · Start Nov 8, 2022 · Primary completion Dec 8, 2022
Drug: Clifutinib with fed state; Clifutinib with fasted state · For: Acute Myeloid Leukemia in Children
Sites: Changchun, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT07211165 · 6 participants · Start Sep 29, 2025 · Primary completion Nov 5, 2025
Drug: [14C]Clifutinib · For: Healthy Adult Male
Sites: Wuxi, China
Newest research
PubMed records naming it or its code names, newest first.
- A phase I study of HEC73543, an oral FLT3 inhibitor: the effect of food on pharmacokinetics after oral dosing in healthy Chinese volunteers.
Wang D, Wu M, Li X, et al. · Front Pharmacol 2025
- Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia.
Liu B, Kang N, Yang F, et al. · J Med Chem 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.